Join the Oncology Voice Network. Join for Free
Why is it so hard to get into oncology
oncology MSL oncology medical science liaison breaking into oncology oncology career advice MSL best practices conference

Why is it so hard to get into oncology


Share This Article


Summary

In this episode, Mary Miao shares her journey and experiences in the oncology field, offering insights into the unique challenges and strategies for breaking into this specialized area. Mary discusses the distinctions between oncology and other therapeutic areas, providing valuable advice for aspiring oncology MSLs. She emphasizes the importance of networking within the oncology community, preparing effectively for MSL roles, and making applications stand out. Mary also highlights the significance of documenting work, maintaining a strong CV, and leveraging LinkedIn for networking. The episode concludes with Mary's advice on embracing humility and continuous learning, along with a promotion for the MSL best practices conference.

My guest today is Mary Miao, Oncology Medical Science Liaison with Immunogen. Mary shares insights on why it is so hard to get into oncology.

This episode is sponsored by Momentum Events and the 2nd MSL Best Practices Summit, virtual event on September 14-15. For more info: https://momentumevents.com/msl-bestpractices/

Mary discusses…

👉 Why there is so much interest in oncology
👉 Why it is difficult to get into the oncology space
👉 How oncology is different from other Therapeutic Areas
👉 What someone needs to do to get into an oncology position
👉 How to prepare yourself to make a successful transition once you're in

Click for Source
oncology MSL, oncology medical science liaison, breaking into oncology, oncology career advice, MSL best practices conference

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How will COVID-19 affect the MSL role and what new skills may emerge as necessary to maintain value, access and future succes

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Explore OVN